MISSISSAUGA, ON, Jan. 20, 2012 /PRNewswire/ - Covalon Technologies
Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical
technologies company, today announced it is presenting its latest
line of advanced wound care and medical coating products, including
ColActive® Plus Ag from January 23rd to
26th at the Annual Arab Health Congress in Dubai, U.A.E. Now in its 37th year, Arab
Health provides an opportunity for the world's leading medical
products manufacturers, wholesalers and distributors to meet the
65,000 medical and scientific community attendees from the
Middle East and beyond.
Since announcing a multi-year distribution
agreement with a Canadian distributor that will export and
distribute Covalon's ColActive Plus Ag wound care dressings in
certain regions of the Middle
East, the interest from medical companies to introduce
Covalon products to the entire region has increased
significantly. ColActive Plus Ag, a patented wound dressing,
is available for distribution and has been cleared for regulatory
purposes in the United States,
Canada and other
jurisdictions. Covalon is also showcasing SurgiClear™ and IV
Clear™ - breathable, clear film antimicrobial surgical wound and IV
securement dressings, along with lubricious and antimicrobial
coated catheters which are available for distribution in
North America, Middle East and international markets.
"We are extremely excited to present at this
year's Arab Health Congress," said Brian
Pedlar, Covalon's Chief Executive Officer. "There has
been great excitement and interest about the ColActive Plus family
of advanced wound dressings from international clinicians and
medical product companies who are looking to license new
breakthrough products."
To learn more about Covalon's products and
services, please visit us at booth SAD 58 in the Dubai World Trade
Centre from January 23rd
to 26th or contact Brian
Pedlar, CEO Covalon Technologies Ltd. at
bpedlar@covalon.com.
About Covalon
Covalon Technologies Ltd. researches, develops
and commercializes new healthcare technologies that help save lives
around the world. Covalon's patented technologies, products and
services address the advanced healthcare needs of medical device
companies, healthcare providers and individual consumers. Covalon's
technologies are used to prevent, detect and manage medical
conditions in specialty areas such as wound care, tissue repair,
infection control, disease management, medical device coatings and
biocompatibility. To learn more about Covalon, visit our website at
www.covalon.com
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
This news release contains forward-looking
statements which reflect the Company's current expectations
regarding future events. The forward-looking statements are often,
but not always, identified by the use of words such as "seek",
"anticipate", "plan, "estimate", "expect", "intend" and statements
that an event or result "may", "will", "should", "could" or "might"
occur or be achieved and other similar expressions. These
forward-looking statements involve risk and uncertainties,
including the difficulty in predicting product approvals,
acceptance of and demands for new products, the impact of the
products and pricing strategies of competitors, delays in
developing and launching new products, the regulatory environment,
fluctuations in operating results and other risks, any of which
could cause results, performance, or achievements to differ
materially from the results discussed or implied in the
forward-looking statements. Many risks are inherent in the
industry; others are more specific to the Company. Investors should
consult the Company's ongoing quarterly filings for additional
information on risks and uncertainties relating to these
forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The Company assumes no
obligation to update or alter any forward-looking statements
whether as a result of new information, further events or
otherwise.
SOURCE Covalon Technologies Ltd.